Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
July 30, 2019 - Bayer announced the FDA approval of Nubeqa (darolutamide), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
